TRT and Fertility: Can Testosterone Therapy Cause Infertility?

A man starts testosterone replacement therapy because of fatigue, low libido, and a low blood test result. A few months in, his serum testosterone is textbook, he feels better, everything looks fine — until the question of a child comes up. Then a semen analysis can show a drastically reduced sperm count, or none at all. This isn't a rare, exotic side effect — it's a direct, predictable consequence of how exogenous testosterone acts on the entire hormonal axis that governs male fertility.

Sperm production and natural testosterone production are controlled by the same hormonal axis — the hypothalamus releases GnRH (gonadotropin-releasing hormone), which prompts the pituitary to secrete LH (luteinizing hormone) and FSH (follicle-stimulating hormone). LH stimulates the Leydig cells in the testes to produce testosterone, while FSH, together with a locally high concentration of testosterone, supports the Sertoli cells that physically 'raise' maturing sperm within the seminiferous tubules. This is a closed, precisely regulated negative-feedback loop: when blood testosterone rises, the hypothalamus and pituitary scale back GnRH and LH, because the body 'sees' that there's already enough testosterone.

The problem is that the brain doesn't distinguish between testosterone produced by the testes themselves and testosterone injected from outside as part of therapy. It only sees a high hormone level in the blood and reacts the same way — cutting GnRH secretion, which in turn drops LH and FSH, sometimes almost to zero. Without LH, the Leydig cells stop being stimulated to produce testosterone locally, inside the testicle itself. Without FSH and without sufficient local stimulation, the Sertoli cells lose the conditions needed for proper spermatogenesis. The testes, deprived of their own hormonal work, shrink over time — the most visible, physical symptom of the same process.

This also explains why the intuitive reasoning of 'if testosterone is high, fertility should be fine' is wrong in the context of TRT. It works the opposite way from naturally low, lifestyle-related testosterone, where better sleep, fat loss, or training can raise both blood testosterone and fertility at the same time, because they don't interfere with the feedback loop itself.

Suppression of spermatogenesis during standard testosterone therapy isn't a rare side effect affecting a handful of patients — it's something you can expect in the vast majority of men using typical therapeutic doses over an extended period. The degree of suppression varies: in some men sperm count drops noticeably but stays measurable (oligospermia); in others it leads to azoospermia, a complete absence of sperm in the ejaculate. The speed and depth of suppression depend on dose, delivery form, injection frequency, and the individual sensitivity of a given man's hypothalamic-pituitary-testicular axis — none of it can be predicted in advance to the day, or to the result, without a semen analysis.

The good news is that in most men, spermatogenesis suppression caused by exogenous testosterone alone (without additional factors, like prior testicular damage) is reversible once therapy is stopped. The bad news is that 'reversible' doesn't mean 'fast' or 'guaranteed 100% for everyone' — returning to baseline sperm count is a process measured in months, not weeks, and in some men, especially older men and those who used TRT the longest, full recovery is incomplete or significantly delayed.

Other observational data point to a similar picture: the median time for sperm count to return to a value considered sufficient for natural conception is typically several months to about a year after stopping exogenous testosterone, and the vast majority of men achieve full recovery within one to two years. The key risk factors for a slower or incomplete return are: older age at the time of stopping, a longer total duration of TRT use, higher doses used, and worse baseline semen quality even before starting therapy.

For men who want to continue TRT while preserving fertility or avoiding noticeable testicular shrinkage, one of the best-documented strategies is adding human chorionic gonadotropin (hCG) to therapy. hCG is structurally similar enough to LH that it binds the same receptors on the Leydig cells and stimulates them to produce testosterone locally, inside the testicle — regardless of the fact that the pituitary, through negative feedback from the externally supplied testosterone, has stopped secreting its own LH. As a result, hCG can keep intratesticular testosterone concentration closer to physiological values despite ongoing TRT — and it's precisely that local level, not the blood level, that matters for spermatogenesis. We cover the mechanism, dosing, and limitations of this strategy in more detail in a separate article on hCG in TRT.

For men with secondary hypogonadism (meaning the problem sits at the hypothalamic or pituitary level, while the testes themselves are capable of normal function once given the right hormonal signal), there's an alternative that entirely sidesteps the problem described above: instead of supplying testosterone from outside, the body can be prompted to increase its own production. This is done with selective estrogen receptor modulators (SERMs) — most commonly clomiphene citrate, and its more selective isomer, enclomiphene.

The mechanism runs opposite to TRT: a SERM blocks estrogen receptors in the hypothalamus, so the brain 'doesn't see' circulating estrogen (produced in part from testosterone aromatization) and, as a result, increases GnRH secretion, and with it LH and FSH. Higher LH stimulates the man's own Leydig cells to produce more testosterone — including that crucial, high intratesticular concentration — while higher FSH further supports the Sertoli cells. The net effect: blood testosterone rises, but through a mechanism that supports, rather than suppresses, sperm production.

The most common mistake seen in clinical practice is starting the fertility conversation only once a couple is already actively trying to conceive and something isn't working — often many months or years after starting TRT. At that point, the options are far more limited: either stop therapy and wait months for spermatogenesis to return (with no 100% guarantee), or start restorative hCG/SERM therapy and wait as well, monitoring semen analysis results along the way.

Sperm banking before starting TRT is an option rarely mentioned, but worth considering, especially for men who aren't yet certain about their family plans but know the therapy will be long-term. It's a relatively cheap, one-time step that eliminates the uncertainty over whether and when fertility will return after years of TRT — regardless of which strategy (hCG, a therapy break, or a SERM) is chosen later.

TRT isn't a therapy to fear in terms of fertility — for many men who've finished building their family, it's a safe, well-studied way to treat genuine hypogonadism. The problem arises when the decision to start therapy is made without factoring in future parenthood plans. If you're a man with low testosterone and aren't sure whether you still want children, treat that question as an integral part of qualifying for treatment, not a topic for later. Discuss realistic options with your doctor — from a SERM, to hCG alongside TRT, to simple sperm freezing — before, not after, starting therapy.